2024
PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchPD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.Peer-Reviewed Original ResearchProstate cancerPatients‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer
Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Ellis S, Loeb S, Schulman‐Green D, Leapman M. ‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer. BJUI Compass 2024, 5: 593-601. PMID: 38873351, PMCID: PMC11168777, DOI: 10.1002/bco2.351.Peer-Reviewed Original ResearchProstate magnetic resonance imagingMagnetic resonance imagingProstate cancerActive surveillanceActive surveillance of prostate cancerGleason Grade Group 1Surveillance of prostate cancerIntermediate-risk prostate cancerMonitoring of prostate cancerMRI-ultrasound fusion biopsyGrade group 1Monitoring prostate cancerGroup 2 tumorsMagnetic resonance imaging scansFusion biopsyLongitudinal follow-upProstate biopsyFollow-upProstateSemi-structured interviews of patientsMRI useQualitative studyGroup 1Interviews of patientsPatients
2023
PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER
Leapman M, Wang R, Long J, Sprenkle P, Ma X, Gross C. PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER. Journal Of Urology 2023, 209: e326. DOI: 10.1097/ju.0000000000003250.01.Peer-Reviewed Original Research“It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance.
Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D, Leapman M. “It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance. Journal Of Clinical Oncology 2023, 41: 334-334. DOI: 10.1200/jco.2023.41.6_suppl.334.Peer-Reviewed Original ResearchActive surveillanceProstate cancerProstate MRIPatient experienceGleason Grade Group 1Prostate cancer active surveillanceIntermediate-risk prostate cancerRisk prostate cancerGrade group 1Group 2 tumorsMRI-ultrasound fusion biopsyMean sample ageHispanics/LatinosInitial diagnosisFusion biopsyProstate biopsyConventional content analysisPatient's perspectiveClinical careGroup 1MRI resultsMRI scansProviders' explanationsCancerPatientsTreatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.Peer-Reviewed Original Research
2022
Physical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic Leukemia
Rodwin RL, Ma X, Ness KK, Kadan-Lottick NS, Wang R. Physical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic Leukemia. JCO Oncology Practice 2022, 18: e1060-e1068. PMID: 35427182, PMCID: PMC9287366, DOI: 10.1200/op.21.00796.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaPediatric acute lymphoblastic leukemiaPhysical therapyPhysical functionLymphoblastic leukemiaNeuromuscular conditionsImpaired physical functionPhysical therapy utilizationPremier Healthcare DatabasePediatric hematologists/oncologistsEarly physical therapyInpatient physical therapyHematologists/oncologistsLong-term healthCohort studyFirst hospitalizationMultivariable analysisTherapy utilizationClinical variablesTeaching hospitalHealthcare databasesPatientsAddress disparitiesHospitalAge 10
2021
Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingHospital referral regionsProportion of patientsProstate cancerGenomic testingCohort studyReferral regionsRetrospective cohort studyProstate cancer carePatient-level analysisCommercial insurance claimsProstate cancer managementUS hospital referral regionsYears of ageProportion of menPatients 40Definitive treatmentCancer careTesting uptakeHRR levelMAIN OUTCOMECancer managementPatientsRegional uptakeMediators of racial disparity in the use of prostate MRI.
Leapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. Mediators of racial disparity in the use of prostate MRI. Journal Of Clinical Oncology 2021, 39: 6554-6554. DOI: 10.1200/jco.2021.39.15_suppl.6554.Peer-Reviewed Original ResearchProstate cancerRacial disparitiesProstate MRIMRI useArea-level measuresObserved racial disparitiesEligible patientsPathologic factorsDual eligibilityWhite patientsBlack patientsSEER regionMedicare databaseCancer careSix-month periodPatientsSociodemographic factorsCancerMRIZip codesOlder AmericansMediatorsDiagnostic toolObserved disparitiesHigh-poverty areasClinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States
Wang X, Zeidan AM, Wang R, Bewersdorf JP, Zhang C, Podoltsev NA, Huntington SF, Gore SD, Ma X. Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia & Lymphoma 2021, 62: 2438-2447. PMID: 33899659, DOI: 10.1080/10428194.2021.1913142.Peer-Reviewed Original ResearchConceptsPopulation-based studyDNA methyltransferase inhibitorRARS patientsRefractory anemiaRing sideroblastsRed blood cell transfusion independenceEnd Results-Medicare databaseLower-risk myelodysplastic syndromesPopulation-based cohortMethyltransferase inhibitorRBC-TIMedian durationMedian survivalOlder patientsTransfusion independenceTreatment initiationMyelodysplastic syndromeClinical effectivenessBetter survivalLenalidomideTreatment groupsPatientsRS statusOlder adultsAnemiaPatterns of Care for Older Patients With Myelofibrosis: A Population-based Study
Meckstroth S, Wang R, Ma X, Podoltsev N. Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study. Clinical Lymphoma Myeloma & Leukemia 2021, 21: e551-e558. PMID: 33648884, DOI: 10.1016/j.clml.2021.01.025.Peer-Reviewed Original ResearchConceptsPatterns of careOlder patientsEnd Results-Medicare databaseJAK inhibitor eraHigh-risk patientsPopulation-based studyUse of ruxolitinibJAK inhibitor ruxolitinibUnited States FoodRuxolitinib approvalMedian ageMedian timeTreatment patternsD claimsCurrent treatmentInhibitor ruxolitinibPatientsBetter outcomesClinical experienceDrug AdministrationMedicare Part BMyelofibrosisRuxolitinibStates FoodNew drugsRegional Adoption of Commercial Gene Expression Testing for Prostate Cancer
Leapman MS, Wang R, Ma S, Gross CP, Ma X. Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer. JAMA Oncology 2021, 7: 52-58. PMID: 33237277, PMCID: PMC7689565, DOI: 10.1001/jamaoncol.2020.6086.Peer-Reviewed Original ResearchConceptsProstate cancerCohort studyGenomic testingTissue-based genomic testsProportion of patientsDynamic cohort studyProstate cancer careProstate cancer screeningHospital referral region levelCommercial health insuranceGene expression testingEligible patientsMedian ageCancer careCancer screeningInclusion criteriaFindings highlight factorsHRR levelMAIN OUTCOMEAdministrative claimsGroup 2Group 1Medicare beneficiariesPatientsMedian household income
2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaDecitabine-treated patientsTransfusion independenceRed blood cell transfusion independenceLarge population-based studyOlder AML patientsRBC transfusion independenceEnd Results-MedicarePopulation-based studyStandard of careAgent azacitidineMedian survivalOlder patientsIntensive therapyAML patientsClinical outcomesClinical benefitMyeloid leukemiaMortality riskPatientsAzacitidineDecitabineOlder adultsOne-thirdMeaningful differences
2019
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†
Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. Leukemia & Lymphoma 2019, 61: 1178-1187. PMID: 31878809, PMCID: PMC7735409, DOI: 10.1080/10428194.2019.1703970.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeExcess blastsRefractory anemiaOverall survival benefitRetrospective cohort studyMedian OSOS benefitRAEB patientsCohort studySurvival benefitTherapy useMyelodysplastic syndromeClinical trialsLower riskMedicare dataPatientsPropensity scoreOlder adultsDiagnosisAnemiaQuartileUnited StatesAssociationEnd resultOSAssociation of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2019, 61: 397-408. PMID: 31570040, PMCID: PMC7732188, DOI: 10.1080/10428194.2019.1663423.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeOverall survivalHMA cyclesHMA therapyProvider experienceCox proportional hazards modelOlder MDS patientsMedian overall survivalPercent of patientsSEER-Medicare dataMultivariate logistic regressionProportional hazards modelHMA initiationClinical outcomesMDS patientsClinical trialsMedian numberHMA treatmentHazards modelPatientsSignificant associationLogistic regressionPopulation-level survivalSurvivalSyndromeRBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leukemia & Lymphoma 2019, 60: 3181-3187. PMID: 31170846, DOI: 10.1080/10428194.2019.1622700.Peer-Reviewed Original ResearchConceptsRBC transfusion independenceLR-MDS patientsTransfusion independenceHMA initiationRBC transfusionClinical effectivenessReal-life clinical effectivenessRed blood cell transfusionLower-risk myelodysplastic syndromesLow-risk MDS patientsRisk MDS patientsBlood cell transfusionRisk myelodysplastic syndromesHMA therapyLR-MDSCell transfusionMost patientsDisease courseMDS patientsMedicare databaseMyelodysplastic syndromePopulation-level estimatesLower oddsTransfusionPatientsAssociation Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma
Huntington SF, Zhu W, Hoag JR, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma. JNCI Cancer Spectrum 2019, 3: pkz030. PMID: 31360905, PMCID: PMC6649837, DOI: 10.1093/jncics/pkz030.Peer-Reviewed Original ResearchPositron emission tomographyStaging positron emission tomographyDiffuse large B-cell lymphomaLarge B-cell lymphomaLow-value imagingNon-Hodgkin lymphomaLow clinical utilityB-cell lymphomaCohort studyAppropriate imagingGuideline recommendationsConsensus guidelinesCancer careLymphoma subtypesCell lymphomaClinical utilityEmission tomographyRoutine useOlder adultsLymphomaPhysician ownershipPet ownershipTomographyImagingPatientsHGG-11. GERMLINE GENETIC PREDISPOSITION TO PEDIATRIC GLIOMA
Muskens I, Walsh K, Zhang C, de Smith A, Morimoto L, Ma X, Wiemels J. HGG-11. GERMLINE GENETIC PREDISPOSITION TO PEDIATRIC GLIOMA. Neuro-Oncology 2019, 21: ii89-ii89. PMCID: PMC6477444, DOI: 10.1093/neuonc/noz036.105.Peer-Reviewed Original ResearchPediatric glioma patientsGBM patientsGene burden testingGlioma patientsPediatric gliomasPediatric brain tumorsPathogenic germline mutationsPopulation-based sampling strategyGermline genetic predispositionCancer predisposition genesRare germline variantsWhole-exome sequencingTreatment strategiesPractice guidelinesBest practice guidelinesBrain tumorsGenetic predispositionCancer-related genesPatientsTP53 mutationsTP53 variantsGlioma riskFrameshift mutationBlood spotsNonsense mutationImpact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal Of The National Comprehensive Cancer Network 2019, 17: 211-219. PMID: 30865915, DOI: 10.6004/jnccn.2018.7095.Peer-Reviewed Original ResearchConceptsImpact of hydroxyureaThrombotic eventsEssential thrombocythemiaEffect of hydroxyureaOlder patientsOverall survivalLower riskMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelHigh-risk essential thrombocythemiaProportional hazards regression modelsRetrospective cohort studyRisk of deathSEER-Medicare databaseHazards regression modelsRisk of thrombosisHU usersFrontline therapyCohort studyCurrent guidelinesStudy populationPatientsReal-world settingThrombosisOlder adults
2018
Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer
Leapman MS, Wang R, Park HS, Yu JB, Weinreb JC, Gross CP, Ma X. Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. Urology 2018, 124: 98-106. PMID: 30107188, DOI: 10.1016/j.urology.2018.07.041.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerProstate magnetic resonance imagingMagnetic resonance imagingProstate cancerDefinitive treatmentPCa diagnosisEnd Results-Medicare databaseResonance imagingMultivariable logistic regression analysisPropensity scoreDiagnosis of PCaUse of MRIConditional logistic regression modelsLogistic regression analysisLogistic regression modelsInitial managementMultivariable analysisGreater oddsPatientsSocioeconomic statusDiagnosisHigher likelihoodRegression analysisDemographic factorsCancer